Baldwin Brothers LLC MA Makes New $55,000 Investment in Illumina, Inc. (NASDAQ:ILMN)

Posted by Defense World Staff on Apr 10th, 2023

Baldwin Brothers LLC MA acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN – Get Rating) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 273 shares of the life sciences company’s stock, valued at approximately $55,000.

Other institutional investors have also made changes to their positions in the company. Brown Brothers Harriman & Co. increased its stake in Illumina by 460.9% during the 1st quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock worth $45,000 after buying an additional 106 shares during the period. Private Trust Co. NA acquired a new position in shares of Illumina in the second quarter worth about $25,000. Zions Bancorporation N.A. lifted its stake in shares of Illumina by 97.6% in the third quarter. Zions Bancorporation N.A. now owns 164 shares of the life sciences company’s stock worth $31,000 after acquiring an additional 81 shares in the last quarter. Guardian Wealth Advisors LLC purchased a new position in Illumina in the third quarter valued at about $33,000. Finally, Massmutual Trust Co. FSB ADV grew its stake in Illumina by 50.0% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 183 shares of the life sciences company’s stock valued at $35,000 after purchasing an additional 61 shares in the last quarter. 87.97% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $229.99 on Monday. The firm’s 50 day moving average is $214.34 and its two-hundred day moving average is $211.16. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.08 and a current ratio of 1.28. Illumina, Inc. has a 52 week low of $173.45 and a 52 week high of $370.54.

Illumina (NASDAQ:ILMN – Get Rating) last issued its quarterly earnings data on Tuesday, February 7th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.11). The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a positive return on equity of 3.79% and a negative net margin of 96.12%. The business’s quarterly revenue was down 9.2% compared to the same quarter last year. During the same period last year, the company earned $0.75 earnings per share. As a group, analysts expect that Illumina, Inc. will post 1.41 EPS for the current fiscal year.

Insider Activity

In related news, SVP Susan H. Tousi sold 500 shares of the stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $211.57, for a total value of $105,785.00. Following the completion of the transaction, the senior vice president now owns 38,276 shares in the company, valued at approximately $8,098,053.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Illumina news, SVP Susan H. Tousi sold 500 shares of the company’s stock in a transaction that occurred on Monday, February 6th. The stock was sold at an average price of $211.57, for a total value of $105,785.00. Following the completion of the sale, the senior vice president now directly owns 38,276 shares in the company, valued at $8,098,053.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Aimee L. Hoyt sold 3,917 shares of the stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $199.06, for a total value of $779,718.02. Following the transaction, the senior vice president now directly owns 2,881 shares of the company’s stock, valued at $573,491.86. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 9,815 shares of company stock valued at $1,974,496. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on ILMN shares. Stifel Nicolaus reduced their target price on Illumina from $285.00 to $235.00 in a research note on Wednesday, February 8th. Cowen decreased their price objective on shares of Illumina from $350.00 to $296.00 in a report on Tuesday, January 10th. Piper Sandler restated an “overweight” rating and issued a $290.00 target price on shares of Illumina in a research note on Wednesday, February 8th. StockNews.com initiated coverage on Illumina in a research note on Thursday, March 16th. They issued a “sell” rating for the company. Finally, Canaccord Genuity Group cut their price objective on Illumina from $330.00 to $300.00 and set a “buy” rating on the stock in a research note on Tuesday, January 17th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and an average price target of $249.40.

Illumina Profile

(Get Rating)

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.